The U.S. Senate Finance Committee has voted to advance Robert F. Kennedy Jr.’s nomination for Secretary of Health and Human ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance. See more on BNTX stock here.

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, personal finance education, top-rated podcasts, and ...

Shares of vaccine companies fell on Tuesday after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead ...

In the case of BioNTech, which is trading at $117.8 as of publishing time, $100 would buy you 0.85 shares of stock. If you're ... or sell a call option at a strike price above where shares are ...

The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the stock from $90.00 to $137.00 in a research report on Friday ...

The firm issued a buy rating and a $172.00 price objective on the stock. A number of other analysts have also weighed in on the stock. Jefferies Financial Group upgraded shares of BioNTech from a ...

BioNTech SE Sponsored ADR (BNTX) closed the last trading session at $112.76, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price ...

Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...